Myeloproliferative disorders: let the partner guide!
Haematologica, 2007 Olivier Rosnet, Daniel Birnbaum
doaj +1 more source
Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country. [PDF]
PLoS One, 2020 Zvizdic Z +4 more
europepmc +1 more source
Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487) [PDF]
, 2003 Arthur I. Radin +9 more
openalex +1 more source
UEG Week 2025 Oral Presentations
United European Gastroenterology Journal, Volume 13, Issue S8, Page S7-S188, October 2025.
wiley +1 more source
Evaluation of Common Genetic Disorders in Myeloproliferative Neoplasms
International Journal of Hematology-Oncology and Stem Cell Research, 2011 Introduction: The myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characterized by excessive production of blood cells by hematopoietic precursors. Typically, they include polycythemia vera (PV), essential thrombocythemia (ET),
Mehrdad Payandeh +7 more
doaj
What is the role of cytogenetic and molecular genetic analysis in the diagnosis of chronic myeloproliferative disorders? [PDF]
, 2003 Roger G. Owen +5 more
openalex +1 more source
Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors. [PDF]
Pulm CircChida-Nagai A +5 more
europepmc +1 more source
Neutralize the neutrophils! Neutrophil β1 /β2 integrin activation contributes to JAK2-V617F–driven thrombosis [PDF]
, 2018 Barbui +4 more
core +2 more sources
SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. [PDF]
EMBO Mol MedCho HJ +19 more
europepmc +1 more source
The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia. [PDF]
CureusSayed WS +4 more
europepmc +1 more source